Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $33.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 65.00% from the stock’s previous close.

Several other equities analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Urogen Pharma Price Performance

Shares of URGN opened at $20.00 on Friday. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The company’s fifty day moving average price is $23.21 and its 200 day moving average price is $20.17. The company has a market capitalization of $936.20 million, a PE ratio of -5.78 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to the consensus estimate of $34.09 million. Analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the insider directly owned 139,025 shares in the company, valued at approximately $3,475,625. This represents a 6.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors have recently bought and sold shares of the stock. Paradigm Biocapital Advisors LP bought a new stake in Urogen Pharma in the third quarter valued at $84,111,000. Soleus Capital Management L.P. acquired a new stake in shares of Urogen Pharma in the 2nd quarter valued at $29,934,000. SG Americas Securities LLC grew its holdings in shares of Urogen Pharma by 607.1% in the 2nd quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after purchasing an additional 986,567 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Urogen Pharma during the 3rd quarter worth about $14,311,000. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Urogen Pharma during the 3rd quarter worth about $13,715,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.